


09/743483


L4 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2001 ACS  
AN 1993:560315 CAPLUS  
DN 119:160315  
TI Preparation of 4-amino-5-pyrimidinecarboxylic acids as ulcer inhibitors  
IN Shimamura, Hiroshi; Terajima, Koji; Kawase, Akito; Ishizuka, Yasuhiro;  
Kimura, Isami; Kanya, Akyoshi; Kataoka, Mikiko; Sato, Makoto  
PA Morishita Ruseru Kk, Japan  
SO Jpn. Kokai Tokkyo Koho, 24 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05112559	A2	19930507	JP 1991-299822	19911018
OS	MARPAT 119:160315				
GI					



AB The title compds. I [R1, R2 = H, lower (halo)alkyl, lower alkoxy, halo;  
R3 = NR5R6, .gtoreq.1 N-contg. (substituted) (un)satd. heterocyclyl; R4 = H, lower alkyl; R5, R6 = H, lower (alkoxy)alkyl, alkenyl, or alkynyl, cycloalkyl, hydroxyalkyl, (substituted) Ph or benzyl; X = NR7, O, S; R7 = H, lower alkyl; n = 0-2; if R1 = R2 = H, X = NH, and n = 1, then R3 .noteq. NMe2, NEtMe, nor morpholino] or their salts are prepd. I (R1 =  
R2 = H, R3 = Cl, R4 = Et, X = NH, n = 0) (prepn. given) in THF was treated with aq. MeNH2 at room temp. for 1 h to give 89% I (R1 = R2 = H, R3 = NHMe, R4 = Et, X = NH, n = 0). I (R1 = Me, R2 = H, R3 = NMe2, R4 = Et, X = NH, n = 1) (II) showed 92% inhibition of acute gastric mucosal damage caused by EtOH, vs. 90%, for omeprazole. A tablet contg. II was formulated.  
IT 150065-44-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and amination of)  
RN 150065-44-4 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-[[[1-methyl-1H-benzimidazol-2-yl)thio]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

09/743483




IT 150065-33-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and chlorination of)

RN 150065-33-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-2-[[[1-methyl-1H-benzimidazol-2-yl]thio]methyl]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 150064-45-2P 150065-20-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as ulcer inhibitor)

RN 150064-45-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(dimethylamino)-2-[[[1-methyl-1H-benzimidazol-2-yl]thio]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 150065-20-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(dimethylamino)-2-[[[1-methyl-1H-benzimidazol-2-yl]sulfinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

09/743483

